Current status of immunomodulatory therapies in HCV infection

Pockros, Paul J.

doi:10.1007/s11901-004-0004-y

Curr hepatitis rep

2004

DOI: 10.1007/s11901-004-0004-y

|View full text |Cite

Current status of immunomodulatory therapies in HCV infection

Paul J. Pockros

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2007

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 50 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

New drugs for hepatitis C virus

Pockros

2007

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

No new therapy has been approved for the treatment of chronic hepatitis C in the last 5 years in the USA since the approval of pegylated interferon (IFN)-alpha(2a) and ribavirin. Multiple new drugs are currently in development and are expected to be approved for use in the USA and/or the EU by 2011-2013. Although the mechanism of action of pegylated IFN and ribavirin are not completely known, it is likely that they will continue to be used in combination regimens for a number of years. Direct antivirals are likely to be the first new drugs to be used in combination with pegylated IFN and ribavirin. Viral resistance will prove to be a significant barrier and require that consolidation therapy with at least 24 weeks of pegylated IFN and ribavirin be used to successfully prevent the selection or emergence of resistant variants. Numerous other compounds, such as ribavirin analogs, long-acting IFNs, hepatoprotectants and immunomodulators, are in development and may replace the drugs that are used currently. The combination of direct antivirals, such as protease and polymerase inhibitors, may rapidly follow in development, as has occurred in HIV drug therapy.

show abstract

New drugs for hepatitis C virus

Pockros

2007

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

Peginterferon-α _2a in the Treatment of Chronic Hepatitis C

Akimov

Adeyemi

2006

Future Virol.

View full text Add to dashboard Cite

Chronic hepatitis C virus infection occurs worldwide and affects over 2.7 million adults in North America. Current standard of care is the combination of pegylated (peg) interferon and ribavirin for 24 weeks in hepatitis C virus genotypes 2 or 3 and at least 48 weeks in chronic hepatitis C virus infection genotypes 1 or 4. Peginterferon-α2a is a 40-kDa linear pegylated molecule that alters the pharmacokinetic properties of unmodified interferon-α. In clinical trials evaluating the combination of peginterferon-α2a and ribavirin in chronic chronic hepatitis C virus infection, sustained virologic response rates have been achieved in 46–52% of patients with genotype 1 and 76–80% of patients with genotypes 2 or 3. Studies on the role of longer treatment duration and retreatment in prior nonresponders are in progress. The main toxicities of peginterferon-α2a are flu-like symptoms and neuropsychiatric disorders, especially depression and cytopenias, and are found in similar rates to those observed with regular inteferon. Future areas of study include the role of peginterferon-α2a in combination with the newer oral chronic hepatitis C virus infection active agents in development.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Current status of immunomodulatory therapies in HCV infection

Cited by 2 publications

References 50 publications

New drugs for hepatitis C virus

New drugs for hepatitis C virus

Peginterferon-α _2a in the Treatment of Chronic Hepatitis C

Contact Info

Product

Resources

About

Current status of immunomodulatory therapies in HCV infection

Cited by 2 publications

References 50 publications

New drugs for hepatitis C virus

New drugs for hepatitis C virus

Peginterferon-α 2a in the Treatment of Chronic Hepatitis C

Contact Info

Product

Resources

About

Peginterferon-α _2a in the Treatment of Chronic Hepatitis C